Skip to main content

Table 4 Prognostic features (PFS) in young patients (≤50 years), Cox regression analyses

From: Are there candidates for high-dose chemotherapy in ovarian carcinoma?

  Univariate analysis Multivariate analysis
  N HR 95CI p-value N HR 95CI p-value
OMS (0-1 vs 2-3) 36 1.76 0.71-4.38 0.22     
FIGO (IIIc vs IV) 52 0.57 0.25-1.33 0.19     
Histology (serous vs others) 52 0.81 0.51-1.56 0.52     
Grade (1-2 vs 3) 31 1.31 0.83-2.08 0.25     
Serous grade 3 (vs others) 31 1.06 0.59-1.88 0.85     
Surgery (complete vs non complete) 52 0.29 0.15-.058 4.97 E-07 51 0.43 0.19-0.94 0.034
Complete clinical remission (Yes vs No) 51 0.22 0.11-0.45 3.65 E-05 51 0.33 0.15-0.74 0.007
CA-125 (normal vs >normal) 44 1.87 0.84-4.16 0.12     
Treatment (CCA vs HDC) 52 2.44 1.14-5.25 0.02 51 2.31 1.06-5.04 0.036
  1. PFS, progression-free survival; N, number of cases with data available; 95CI, 95% confidence interval; HR, hazard ratio; OMS, performance status; CCA, conventional chemotherapy alone; HDC, high-dose chemotherapy.